BioMarin Pharmaceutical Inc. $BMRN Shares Bought by Sio Capital Management LLC

Sio Capital Management LLC lifted its holdings in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) by 59.5% in the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 225,114 shares of the biotechnology company’s stock after buying an additional 83,980 shares during the quarter. BioMarin Pharmaceutical comprises 4.7% of Sio Capital Management LLC’s portfolio, making the stock its 8th biggest holding. Sio Capital Management LLC owned about 0.12% of BioMarin Pharmaceutical worth $12,375,000 as of its most recent SEC filing.

A number of other hedge funds have also recently added to or reduced their stakes in the stock. Avantax Advisory Services Inc. raised its stake in shares of BioMarin Pharmaceutical by 8.4% in the first quarter. Avantax Advisory Services Inc. now owns 6,447 shares of the biotechnology company’s stock worth $456,000 after acquiring an additional 497 shares during the last quarter. Federated Hermes Inc. increased its holdings in shares of BioMarin Pharmaceutical by 3.4% in the first quarter. Federated Hermes Inc. now owns 19,647 shares of the biotechnology company’s stock valued at $1,389,000 after purchasing an additional 648 shares in the last quarter. Natixis Advisors LLC raised its position in BioMarin Pharmaceutical by 68.3% in the 1st quarter. Natixis Advisors LLC now owns 33,226 shares of the biotechnology company’s stock worth $2,349,000 after purchasing an additional 13,488 shares during the last quarter. Commerce Bank bought a new position in BioMarin Pharmaceutical in the 1st quarter worth approximately $222,000. Finally, PNC Financial Services Group Inc. lifted its holdings in BioMarin Pharmaceutical by 5.3% during the 1st quarter. PNC Financial Services Group Inc. now owns 12,816 shares of the biotechnology company’s stock worth $906,000 after buying an additional 650 shares in the last quarter. Institutional investors own 98.71% of the company’s stock.

BioMarin Pharmaceutical Stock Down 1.6%

Shares of NASDAQ:BMRN opened at $55.03 on Tuesday. The company has a 50 day moving average price of $53.82 and a two-hundred day moving average price of $56.05. The company has a debt-to-equity ratio of 0.10, a quick ratio of 3.60 and a current ratio of 4.83. The company has a market capitalization of $10.57 billion, a PE ratio of 20.69, a PEG ratio of 0.68 and a beta of 0.33. BioMarin Pharmaceutical Inc. has a 52 week low of $50.76 and a 52 week high of $73.51.

BioMarin Pharmaceutical (NASDAQ:BMRN) last released its quarterly earnings data on Monday, October 27th. The biotechnology company reported $0.12 EPS for the quarter, missing analysts’ consensus estimates of $0.32 by ($0.20). The firm had revenue of $776.13 million during the quarter, compared to the consensus estimate of $782.42 million. BioMarin Pharmaceutical had a net margin of 16.82% and a return on equity of 9.53%. BioMarin Pharmaceutical’s quarterly revenue was up 4.1% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.91 EPS. BioMarin Pharmaceutical has set its FY 2025 guidance at 3.500-3.600 EPS. Analysts forecast that BioMarin Pharmaceutical Inc. will post 3.15 earnings per share for the current year.

Wall Street Analyst Weigh In

BMRN has been the subject of a number of recent research reports. Zacks Research downgraded BioMarin Pharmaceutical from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, August 13th. Stifel Nicolaus reiterated a “hold” rating and issued a $61.00 price objective (down from $73.00) on shares of BioMarin Pharmaceutical in a research report on Thursday, November 6th. Wedbush restated an “outperform” rating and set a $94.00 target price on shares of BioMarin Pharmaceutical in a research report on Tuesday, October 28th. Weiss Ratings reaffirmed a “sell (d)” rating on shares of BioMarin Pharmaceutical in a research note on Monday, November 24th. Finally, Barclays dropped their price target on shares of BioMarin Pharmaceutical from $86.00 to $80.00 and set an “overweight” rating for the company in a research note on Tuesday, October 28th. Sixteen equities research analysts have rated the stock with a Buy rating, six have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $89.91.

BioMarin Pharmaceutical Company Profile

BioMarin Pharmaceutical Inc develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease.